Nautilus Biotechnology, Inc.
NAUTNASDAQHealthcareBiotechnology

About Nautilus Biotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Company Information

CEOSujal Patel
Founded2016
Employees155
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone206 333 2001
Address
2701 Eastlake Avenue East Seattle, Washington 98102 United States

Corporate Identifiers

CIK0001808805
CUSIP63909J108
ISINUS63909J1088
EIN98-1541723
SIC3826

Leadership Team & Key Executives

Sujal M. Patel
Co-Founder, Chief Executive Officer, President, Secretary and Director
Dr. Parag Mallick Ph.D.
Co-Founder, Chief Scientist and Director
Kentaro Suzuki
Chief Marketing Officer
Anna Mowry
Chief Financial Officer and Treasurer
Matthew B. Murphy ESQ.
General Counsel
Gwen E. Weld
Chief People Officer
Dr. Subra Sankar Ph.D.
Senior Vice President of Product Development